Understand what your iron blood health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Thrombophilia and the pro-clotting side of blood chemistry
Thrombophilia biomarkers are measurable signals that reveal an inherited or acquired tilt toward forming blood clots. They read the balance in your clotting system—the machinery that seals injuries (coagulation) and the built-in brakes that keep blood flowing (anticoagulants). Core markers include the amount or activity of the natural brakes antithrombin, protein C, and protein S (SERPINC1, PROC, PROS1); DNA variants that make clotting harder to turn off, such as Factor V Leiden (F5 R506Q) and the prothrombin G20210A change (F2); and autoimmune flags that trigger clotting on healthy surfaces, the antiphospholipid antibodies (anticardiolipin, anti–β2 glycoprotein I, lupus anticoagulant). Together they show whether your blood’s “stop” signals are weak, its “go” signals are too strong, or the system is being misdirected. Testing turns this biology into practical decisions: explaining unexpected clots, estimating recurrence risk, tailoring the intensity and duration of anticoagulation, and planning protection around life events that raise clot risk (surgery, immobilization, pregnancy, or estrogen use). It can also guide when family members might benefit from evaluation.
Why these markers map your clotting set-point
Thrombophilia blood testing looks at how readily your blood forms clots by integrating signals from coagulation proteins, platelets, vessel wall inflammation, and immune stress. These biomarkers matter because clots form at the intersection of metabolism, inflammation, and hemostasis, affecting lungs (pulmonary embolism), brain (stroke), heart, and pregnancy. Homocysteine is typically about 5–15; optimal tends toward the lower end because higher levels stiffen endothelium and make platelets stickier. CRP is healthiest very low; rising values signal inflammatory drive that amplifies clotting. Platelets are generally 150–400, with risk increasing when counts climb and platelets are activated. The neutrophil‑to‑lymphocyte ratio (NLR) is usually around 1–3; lower‑to‑mid values reflect a calmer immune tone, while higher ratios track systemic stress and prothrombotic inflammation. When these markers run low, they tell a different physiologic story. Low homocysteine generally reflects adequate methylation capacity and does not promote thrombosis. Very low CRP indicates quiet vascular inflammation. Low‑normal NLR suggests minimal stress; if extremely low due to lymphocyte predominance, it can accompany certain viral illnesses rather than clotting. Low platelets reduce clotting capacity and may cause easy bruising, nosebleeds, or heavy periods; in pregnancy, platelets can drift lower yet remain normal, while pregnancy overall increases clot tendency through other pathways. Children normally have slightly lower NLRs; women on estrogen have higher clot risk despite normal counts. Big picture, these tests sit alongside specific thrombophilia assays (e.g., protein C/S, antithrombin, antiphospholipid antibodies, factor mutations) to map your coagulation set‑point. They connect vascular health, metabolism, and immune activity to future risk of deep vein thrombosis, pulmonary embolism, stroke, cardiovascular events, and adverse pregnancy outcomes.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
What this panel adds to a thrombophilia workup
Thrombophilia blood testing provides insight into your body’s tendency to form blood clots, a process that can impact cardiovascular health, energy delivery, brain function, and even reproductive outcomes. At Superpower, we assess four key biomarkers—Homocysteine, C-reactive protein (CRP), platelets, and the neutrophil-to-lymphocyte ratio (NLR)—to build a systems-level picture of your clotting risk and overall vascular stability. Homocysteine is an amino acid that, when elevated, can damage blood vessel linings and promote clot formation. CRP is a marker of inflammation; higher levels signal increased inflammatory activity, which can make blood more prone to clotting. Platelets are cell fragments essential for normal clotting, but too many or too few can disrupt the balance between bleeding and clotting. The NLR reflects the balance between two types of white blood cells and serves as a general marker of immune system activation and inflammation, both of which can influence clotting risk. Together, these biomarkers reveal how well your body maintains the delicate balance between preventing excessive bleeding and avoiding dangerous clots. Stable, healthy levels suggest your vascular and immune systems are working in harmony, supporting efficient circulation and organ function. Imbalances may indicate a higher risk for clot-related complications, affecting everything from heart and brain health to fertility. Interpretation of these results depends on factors like age, pregnancy, acute illness, medications (such as anticoagulants or hormone therapy), and laboratory methods. These variables can shift biomarker levels, so results are always considered in context.
Frequently Asked Questions
References
- Connors JM (2017). Thrombophilia testing and venous thrombosis. *The New England Journal of Medicine*, *377*(12), 1177-1187. https://doi.org/10.1056/NEJMra1700365
- Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, Lang E, Moll S, Myers T, Bhatt M, Chai-Adisaksopha C, Colunga-Lozano LE, Karam SG, Zhang Y, Wiercioch W, Schunemann HJ, Iorio A (2023). American Society of Hematology 2023 guidelines for management of venous thromboembolism: Thrombophilia testing. *Blood Advances*, *7*(22), 7101-7138. https://doi.org/10.1182/bloodadvances.2023010177
- den Heijer M, Lewington S, Clarke R (2005). Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. *Journal of Thrombosis and Haemostasis*, *3*(2), 292-299. https://doi.org/10.1111/j.1538-7836.2005.01141.x
- Garcia D, Erkan D (2018). Diagnosis and management of the antiphospholipid syndrome. *The New England Journal of Medicine*, *378*(21), 2010-2021. https://doi.org/10.1056/NEJMra1705454
- National Heart, Lung, and Blood Institute. (2022). *Venous thromboembolism*. https://www.nhlbi.nih.gov/health/venous-thromboembolism
